(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/099682 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01) *A61K 47/50* (2017.01)
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/EP2022/084105

(22) International Filing Date:
01 December 2022 (01.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21306690.5 02 December 2021 (02.12.2021) EP
63/383,337 11 November 2022 (11.11.2022) US

(71) Applicant: **SANOFI** [FR/FR]; 46 avenue de la Grande Armée, 75017 PARIS (FR).

(72) Inventors: **CHADJAA, Mustapha**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 PARIS (FR). **LE BAIL, Nathalie**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 PARIS (FR). **SOUFFLET, Christine**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 PARIS (FR). **DENNIS, Phillip**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **BENSFIA, Samira**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **CABINET NONY**; 11 rue Saint-Georges, 75009 PARIS (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: CEACAM5 ADC–ANTI-PD1/PD-L1 COMBINATION THERAPY

(57) Abstract: Provided are methods for combination treatment of a cancer using an antibody-drug conjugate (ADC) targeting CEACAM5 and an anti-PD-1 antibody or anti-PD-L1 antibody, optionally together with a platinum-containing agent such as cisplatin or carboplatin with or without pemetrexed. In certain embodiments the ADC is tusamitamab ravtansine. In certain embodiments the anti-PD-1 antibody is pembrolizumab. In certain embodiments, the cancer is nonsquamous non-small cell lung cancer (NSQ NSCLC). In certain embodiments, the cancer is advanced or metastatic NSQ NSCLC.

WO 2023/099682 A1